Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY

Shares of Laurus Labs rose 3.79% to Rs 2,329 during Friday's trading session after the pharmaceutical company reported strong Q2FY27 results, with revenue rising 33% year-on-year (YoY) and net profit more than doubling.

The strong quarterly performance was driven by sustained growth in its contract development and manufacturing organisation (CDMO) business and continued momentum in its Affordable Medicines division.

In its exchange filing, Laurus Labs, a research and development-driven pharmaceutical and biotechnology company, reported revenue of Rs 2,206 crore for Q2FY27, compared with Rs 1,653 crore in the corresponding quarter last year.


Net profit surged 126% YoY to Rs 441 crore from Rs 195 crore in Q2FY26, while EBITDA climbed 78% to Rs 762 crore from Rs 429 crore in the year-ago quarter.

The company's EBITDA margin stood at 34.5% during the quarter, while gross margin expanded to 63% from 59.9% in Q2FY26.

Commenting on the performance, Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered another record quarter in terms of revenue and profitability, reflecting the strength of its CDMO platform and Affordable Medicines portfolio.

He highlighted the operationalisation of the company's first commercial-scale peptide manufacturing plant in Vizag, adding that significant capacity expansion was already underway to address rising demand for peptide therapeutics. The company also announced targeted investments in oligonucleotides and peptide-resin technologies to strengthen its integrated CDMO capabilities.

Also Read | Reliance Industries shares down 26% in 2026: Here’s how to trade RIL stocks on results day

Laurus Labs H1FY27 performance

Laurus Labs reported revenue of Rs 4,233 crore for the first half of FY27, registering 31% YoY growth.

EBITDA for the six-month period stood at Rs 1,406 crore, with a margin of 33.2%. The EBITDA margin improved by 7.8 percentage points, supported by higher CDMO revenue and improving operating leverage.

Gross margin expanded by more than 3.3 percentage points to 62.9% during the first half.

The company reported capital expenditure at 20% of revenue, reflecting continued investments in expanding its manufacturing network and strengthening niche capabilities.

Also Read | Maxwell Engineering, HGS India among 4 SME IPOs to open on October 30; issues to raise Rs 201 crore

Laurus Labs declares interim dividend

Alongside its quarterly results, Laurus Labs declared an interim dividend of Re 1 per share.

The company said its investments in manufacturing capacity and specialised technology platforms were aimed at strengthening its capabilities and expanding its integrated CDMO offerings.

Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here